Home›Companies›Biotech & Pharma›UbiVac

Ubivac, Inc.

Develops cancer immunotherapies and therapeutic vaccines for people with cancer.

Updated Nov 9, 2026·Latest SEC filing Aug 27, 2026·Suggest an edit

About UbiVac

UbiVac is a private company based in Portland, Oregon. It has reported $2,760,773 raised in seven offerings on Form D since August 2017. Its chief executive is Bernard Fox, Ph.D..

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 2, 2026Aug 27, 2026$80,000target not set2$40,000Equity, OptionsRule 506(b)Form D ↗
Jan 19, 2025Mar 11, 2025$35,000of $4.4M target2$17,500Equity, Debt, OptionsRule 506(b)Form D ↗
Jun 3, 2024Jun 12, 2024amended Sep 23, 2024$150,000target not set3$50,000Equity, Debt, OptionsRule 506(c)Form D/A ↗1 earlier filing
Oct 31, 2023Nov 8, 2023$100,000target not set2$50,000Equity, Debt, OptionsRule 506(b)Form D ↗
Apr 8, 2022Apr 15, 2022$250,000of $5.0M target1$250KEquityRule 506(c)Form D ↗
May 21, 2018May 25, 2018amended Apr 29, 2019$1,945,773of $3.0M target10$194KEquityRule 506(b)Form D/A ↗1 earlier filing
Jul 21, 2017Aug 4, 2017$200,000of $2.0M target2$100KDebt, Options, Securities on exerciseRule 506(b)Form D ↗
Total, seven offerings$2,760,773

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on UbiVac's Form D filed Aug 27, 2026.

HD
Hong-Ming Hu, Ph.D.
Founder and director
BI
Bernard A. Fox, III
Cofounder and COO
BD
Bernard Fox, Ph.D.
Founder and CEO, director

Earlier filings also listed Nancy Lime (executive officer, last listed Nov 2023), Steve Buhaly (executive officer, last listed Apr 2022), Jon Wigginton, M.D. (director, last listed Apr 2022), Bernard Fox, MBA (chief development officer, last listed Apr 2022) and Bernard Fox III, MBA (chief financial and operating officer, last listed Aug 2017).

Sources

  1. SECUBIVAC, INC. Form D, filed Jun 12, 2024
  2. SECUBIVAC, INC. Form D, filed May 25, 2018
  3. SECUBIVAC, INC. filing history
  4. CompanyUbiVac contact
  5. CompanyUbiVac overview
  6. CompanyUbiVac board of directors
  7. CompanyCoronavirus vaccine clinical trial announcement
  8. CompanyBristol Myers Squibb clinical trial collaboration